Technical Analysis for XBIO - Xenetic Biosciences, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Flat | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | 0.00% | |
| Crossed Above 200 DMA | Bullish | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| NR7 | Range Contraction | 4.28% | |
| NR7-2 | Range Contraction | 4.28% | |
| Narrow Range Bar | Range Contraction | 4.28% | |
| Inside Day | Range Contraction | 4.28% | |
| Down 3 Days in a Row | Weakness | 4.28% | |
| NR7 | Range Contraction | 3.32% | |
| Narrow Range Bar | Range Contraction | 3.32% |
| Alert | Time |
|---|---|
| Fell Below Previous Day's Low | 2 days ago |
| Possible NR7 | 3 days ago |
| Possible Inside Day | 3 days ago |
| Down 3% | 4 days ago |
| Fell Below Previous Day's Low | 4 days ago |
Get a Trading Assistant
- Earnings date: 05/09/2024
Xenetic Biosciences, Inc. Description
Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research and development of certain pharmaceutical products for use in humans that includes the use of the Company's platform technologies that enables the creation of drug therapies primarily for orphan indications. The Company's technologies include PolyXen, Virexxa, OncoHist and ImuXen. The Company is focused primarily on developing its lead product candidates, including ErepoXen, Virexxa and OncoHist, and PolyXen technology. The Company's lead product candidate ErepoXen, a polysialylated form of erythropoietin (EPO) for the treatment of anemia in pre-dialysis patients with chronic kidney disease, and Food and Drug Administration (FDA) orphan designated oncology therapeutics Virexxa and OncoHist for the treatment of progesterone receptor negative endometrial cancer and refractory Acute Myeloid Leukemia, respectively. It is also developing PSA-FVIII.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Pharmacy Pharmaceutical Products FDA Acute Myeloid Leukemia Kidney Disease Dialysis Anemia Chronic Kidney Disease Drug Therapies Platform Technologies Endometrial Cancer Refractory Acute Myeloid Leukemia Erythropoietin Growth Factors
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 5.97 |
| 52 Week Low | 2.8696 |
| Average Volume | 5,562 |
| 200-Day Moving Average | 3.90 |
| 50-Day Moving Average | 4.03 |
| 20-Day Moving Average | 3.86 |
| 10-Day Moving Average | 3.80 |
| Average True Range | 0.24 |
| RSI (14) | 50.25 |
| ADX | 10.27 |
| +DI | 23.02 |
| -DI | 16.16 |
| Chandelier Exit (Long, 3 ATRs) | 3.62 |
| Chandelier Exit (Short, 3 ATRs) | 4.23 |
| Upper Bollinger Bands | 4.16 |
| Lower Bollinger Band | 3.56 |
| Percent B (%b) | 0.57 |
| BandWidth | 15.67 |
| MACD Line | -0.06 |
| MACD Signal Line | -0.07 |
| MACD Histogram | 0.0124 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.27 | ||||
| Resistance 3 (R3) | 4.25 | 4.10 | 4.21 | ||
| Resistance 2 (R2) | 4.10 | 4.01 | 4.11 | 4.19 | |
| Resistance 1 (R1) | 4.00 | 3.95 | 4.05 | 4.02 | 4.17 |
| Pivot Point | 3.86 | 3.86 | 3.88 | 3.87 | 3.86 |
| Support 1 (S1) | 3.76 | 3.76 | 3.81 | 3.78 | 3.63 |
| Support 2 (S2) | 3.61 | 3.70 | 3.62 | 3.61 | |
| Support 3 (S3) | 3.51 | 3.61 | 3.59 | ||
| Support 4 (S4) | 3.53 |
